Transgene Stock

Transgene EBITDA per Share

The EBITDA per Share of Transgene (TNG.PA) as of Aug 4, 2026 is -0.29 EUR. In the previous year, EBITDA per Share was -0.28 EUR — a change of 4.04% (lower).

EBITDA per Share

-0.29EUR

YoY

4.04%

Last updated:

EBITDA per Share of Transgene is 2026 -0.29 EUR. EBITDA per Share of Transgene was 2025 -0.28 EUR. It decreases by 4.04% lower compared to the previous year.
Access this data via the Eulerpool API
Get Free API Key

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

EBITDA per Share of Transgene is -0.29 EUR in 2026.

EBITDA per Share of Transgene changed from -0.28 EUR to -0.29 EUR, representing a 4.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Transgene since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API
Get Free API Key

Income Statement — Transgene

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Transgene